Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2003-07-31
2010-02-16
Myers, Carla (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C536S023500, C536S024310, C436S063000, C436S064000
Reexamination Certificate
active
07662553
ABSTRACT:
The invention provides compositions and methods for determining the increased risks for recurrence of certain cancers and the likelihood of successful treatment with one or both of chemotherapy and radiation therapy. The methods comprising determining the type of genomic polymorphism present in a predetermined region of the gene of interest isolated from the subject or patient. Also provided are nucleic acid probes and kits for determining a patient's cancer risk and treatment response.
REFERENCES:
patent: 5705336 (1998-01-01), Reed et al.
patent: 5985561 (1999-11-01), Kimberly et al.
patent: 6573052 (2003-06-01), Danenberg
patent: 6602670 (2003-08-01), Danenberg
patent: 6716581 (2004-04-01), Lenz et al.
patent: 7049059 (2006-05-01), Danenberg
patent: 7132238 (2006-11-01), Danenberg
patent: 2004/0067519 (2004-04-01), Lenz et al.
patent: 2004/0265813 (2004-12-01), Takechi et al.
patent: 2005/0064417 (2005-03-01), Watier et al.
patent: 2006/0008825 (2006-01-01), Levy et al.
patent: 2006/0115827 (2006-06-01), Lenz
patent: 2006/0121526 (2006-06-01), Danenberg
patent: 2007/0207486 (2007-09-01), Lenz
patent: 2007/0218487 (2007-09-01), Lenz
patent: 2007/0244083 (2007-10-01), Lenz
patent: WO 01/36686 (2001-05-01), None
patent: WO 01/36686 (2001-05-01), None
patent: WO 01/75175 (2001-10-01), None
patent: WO 01/75175 (2001-10-01), None
patent: WO 01/75175 (2001-10-01), None
patent: WO 02/057489 (2002-07-01), None
patent: WO 02/061128 (2002-08-01), None
patent: WO 2004/011625 (2004-02-01), None
patent: WO 2004/011625 (2004-02-01), None
patent: WO 2004/037852 (2004-05-01), None
patent: WO 2007/064957 (2007-06-01), None
patent: PCT/US2008/000650 (2008-01-01), None
patent: PCT/US2008/000651 (2008-01-01), None
patent: PCT/US2008/000660 (2008-01-01), None
patent: PCT/US2008/000661 (2008-01-01), None
patent: PCT/US2008/000685 (2008-01-01), None
patent: PCT/US2008/000715 (2008-01-01), None
patent: PCT/US2008/051527 (2008-01-01), None
Hirschhorn et al. Genetics in Medicine. 2002. 4(2): 45-61.
Halushka et al. Nature. Jul. 1999. 22: 239-247.
Yu et al. Mutation Research. 1997. 382: 13-20.
Yu et al. Cancer Letters. 2000. 151: 127-132.
Winter et al. Oncogene. 2005. 24: 2110-2113.
Lee et al. Proceedings American Association Cancer Research. 2005. 46: Abstract 1496.
Grau et al. Journal of Clinical Oncology. 2005. 23: 511S.
Viguier et al. Clinical Cancer Research. 2005. 11: 6212-6217.
Britten et al. International Journal of Cancer. 2000. 89: 453-457.
Kang et al. Experimental and Molecular Medicine. 2006. 38: 320-.
Culy et al. Drugs. Oct. 2000. 60(4): 895-924.
Abdel-Rahman, S. et al. “Polymorphisms in DNA Repair Gene XRCC1 Increases the Risk of Colorectal Cancer in Egypt”Proceedings of the American Association for Cancer Research(Mar. 2000) 41:595, No. 3791 .
Board, P.G. et al. “Isolation of a cDNA clone and localization of the humnan glutathione S-transferase 3 genes to chromosome bands 11q13 and 12q13-14”Ann. Hum. Genet. (1989) 53:205-213.
Caldecott, K.W. et al. “XRCC1, A Central Regulator of Single Strand Break Repair and Base Excision Repair”Proceedings of the American Association for Cancer Research(Mar. 2000) 41:891, No. 526.
Duell, E.J. et al. “Polymorphisms in the DNA repair genesXRCC1andERCC2and biomarkers of DNA damage in human blood mononuclear cells”Carcinogenesis(May 2000) 21(5):965-971.
Divine, K.K. et al. “The XRCC1 399 GLN Polymorphism:. Potential Association with Lung Adenocarcinoma”Proceedings of the American Association for Cancer Research(Mar. 2000) 41:591, No. 3762.
Edler, D. et al. “Thymidylate Synthase Expression: An Independent Prognostic Factor for Local Recurrence, Distant Metastasis, Disease-free and Overall Survival in Rectal Cancer”Clinical Cancer Research(Apr. 2000) 6:1378-1384.
Halpern, J. “Maximally Selected Chi Square Statistics for Small Samples”Biometrics(Dec. 1982) 38:1017-1023.
Harries, L.W. et al. “Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer”Carcinogenesis(1997) 18(4):641-644.
Heidelberger, C. et al. “Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds”Nature(Mar. 30, 1957) 179:663-666.
Horie, N. et al. “Functional Analysis and DNA Polymorphism of the Tandemly Repeated Sequences in the 5′-terminal Regulatory Region of the Human Gene for Thymidylate Synthase”Cell Structure and Function(1995) 20:191-197.
Horikoshi, T. et al. “Quantitation of Thymidylate Synthase, Dihydrofolate Reductase, and DT-Diaphorase Gene Expression in Human Tumors Using the Polymerase Chain Reaction”Cancer Res. (Jan. 1, 1992) 52:108-116.
Howie, A.F. et al. “Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues”Carcinogenesis(1990) 11(3):451-458.
Hu, J.J. et al. “Genetic Polymorphism of DNA Repair in Human Prostate Cancer Risk”Proceedings of the American Association for Cancer Research(Mar. 2000) 41:596, No. 3798.
Ishikawa, Y. et al. “Dihydropyrimidine Dehydrogenase Activity and Messenger RNA Level May Be Related to the Antitumor Effect of 5-Fluorouracil on Human Tumor Xenografts in Nude Mice”Clin. Cancer Res. (Apr. 1999) 5:883-889.
Leichman, C.G. et al. “Quantitation of Intratumoral Thymidylate Synthase Expression Predicts for Disseminated Colorectal Cancer Response and Resistance to Protracted-Infusion Fluorouracil and Weekly Leucovorin”J. Clinical Oncology(Oct. 1997) 15(10):3223-3229.
Mannervik, B. “The Isoenzymes of Glutathione Transferase”Adv. Enzymol. (1985) 57:357-417.
Miller, R. and D. Siegmund “Maximally Selected Chi Square Statistics”Biometrics(Dec. 1982) 38:1011-1016.
Moscow, J.A. et al. “Expression of Anionic Glutathione-S-transferase and P-Glycoprotein Genes in Human Tissues and Tumors”Cancer Res. (Mar. 15, 1989) 49:1422-1428.
Nishimura, T. et al. “Association between expression of glutathione-associated enzymes and reponse to platinum-based chemotherapy in head and neck cancer”Chemico-Biological Interactions(1998) 111-112:187-198.
Peters, W.H.M. et al. “Expression of Drug-Metabolizing Enzymes and P-170 Glycoprotein in Colorectal Carcinoma and Normal Mucosa”Gastroenterology(Aug. 1992) 103:448-455.
Salonga, D. et al. “Colorectal Tumors Responding to 5-Fluorouracil Have Low Gene Expression Levels of Dihydropyrimidine Dehydrogenase, Thymidylate Synthase, and Thymidine Phosphorylase”Clin. Cancer Res. (Apr. 2000) 6:1322-1327.
Singh, S.V. et al. “Differential expression of glutathione S-transferase, glutathione peroxidase, and glutathione reductase in normal and malignant human breast tissues”Cancer Letters(1990) 51:43-48.
Stern, M.C. et al. “DNA Repair Gene XRCC1 Polymorphisms, Smoking and Bladder Cancer Risk”Proceedings of the American Association for Cancer Research(Mar. 2000) 41:592, No. 3771.
Sweeney, C. et al. “Association between Survival after Treatment for Breast Cancer and Glutathione S-Transferase P1 lle105Val Polymorphism”Cancer Res. (Oct. 15, 2000) 60:5621-5624.
Terrier, P. et al. “An Immunohistochemical Study of Pi Class Glutathione S-Transferase Expression in Normal Human Tissue”Am. J. Pathol. (Oct. 1990) 137(4):845-853.
Tsuchida. S. and K. Sato “Glutathione Transferases and Cancer”Rev. Biochem. Mol. Biol. (1992) 27(4,5):337-384.
van Lieshout, E.M.M. “Polymorphic Expression of the GlutathioneS-TransferaseP1Gene and Its Susceptibility to Barrett's Esophagus and Esophageal Carcinoma”Cancer Res. (Feb. 1, 1999) 59(3):586-589.
Watson, M.A. et al. Human glutathioneS-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distributionCarcinogenesis(1998) 19(2):275-280.
Wei, X. et al. “Molecular Basis of the Human Dihydropyrimidine Dehydrogaenase Deficiency and 5-Fluorouracil Toxic
Lenz Heinz-Josef
Park David (Jong-Han)
Stoehlmacher Jan
Foley & Lardner LLP
Konski Antoinette F.
Myers Carla
University of Southern California
LandOfFree
Polymorphisms in the ERCC1 gene for predicting treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymorphisms in the ERCC1 gene for predicting treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphisms in the ERCC1 gene for predicting treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4182518